Table 4.
Base case analysis of NEPA compared to other treatments in HEC and MEC.
| HEC | MEC | |||
|---|---|---|---|---|
| APPA(PO) | NEPA(PO) | PA(PO) | NEPA(PO) | |
| COSTS (£) | ||||
| Treatment acquisition | 105.48 | 71.17 | 56.61 | 69.72 |
| CINV episode management | 18.81 | 8.72 | 28.02 | 21.56 |
| Inpatient care | 15.31 | 7.10 | 22.80 | 17.55 |
| Rescue medication | 0.46 | 0.21 | 0.68 | 0.53 |
| Outpatient/physician care | 3.04 | 1.41 | 4.53 | 3.49 |
| Cost in acute phase | 1.87 | 1.26 | 12.59 | 9.73 |
| Cost in delayed phase | 16.94 | 7.47 | 15.44 | 11.83 |
| Cost of treated related AEs | 0.00 | 0.00 | 0.00 | 0.00 |
| Indirect costs, other expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Indirect costs, workday loss | 0.00 | 0.00 | 0.00 | 0.00 |
| Total costs | 124.29 | 79.89 | 84.63 | 91.28 |
| HEALTH OUTCOMES | ||||
| Average emesis-free days | 4.348 | 4.703 | 3.769 | 4.068 |
| Average CINV-free days | 4.273 | 4.500 | 3.428 | 3.653 |
| Emesis-free patients (%) | 77.6 | 89.6 | 66.6 | 74.3 |
| CINV-free patients (%) | 77.6 | 83.0 | 57.9 | 63.8 |
| Quality-adjusted life days | 4.055 | 4.263 | 3.619 | 3.802 |
| Quality-adjusted life years | 0.011 | 0.012 | 0.010 | 0.010 |
| COST/OUTCOMES (£) | ||||
| Cost per emesis-free day | Dominant | 86 | ||
| Cost per CINV-free day | Dominant | 113 | ||
| Cost per QALDs gain | Dominant | 36 | ||
| Cost per QALYs gain | Dominant | 13,318 | ||
| WILLINGNESS-TO-PAY (£30,000) | ||||
| Net monetary benefit | £62 | £8 | ||
| Acceptability | 97% | 88% | ||
AE: adverse event; APPA: aprepitant+palonosetron+dexamethasone; CINV: chemotherapy induced nausea and vomiting; HEC: highly emetogenic chemotherapy; MEC: moderately emetogenic chemotherapy; NEPA: netupitant+palonosetron+ dexamethasone; PA: palonosetron+dexamethasone; PO: per os (by mouth); QALD: quality-adjusted life-days; QALY: quality-adjusted life-years.